JAGX - Jaguar Health, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
JAGX price evolution
JAGX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.27 | $16.05 | $11.67 | $6.47 |
| Short term investments | ||||
| Net receivables | $1.31 | $1.36 | $1.71 | $2.18 |
| Inventory | $9.67 | $9.56 | $9.02 | $9.19 |
| Total current assets | $36.64 | $40.11 | $33.71 | $27.96 |
| Long term investments | ||||
| Property, plant & equipment | $1.53 | $1.66 | $1.77 | $1.67 |
| Goodwill & intangible assets | $19.41 | $19.63 | $20.12 | |
| Total noncurrent assets | $21.35 | $21.68 | $22.8 | |
| Total investments | ||||
| Total assets | $58.47 | $61.46 | $55.39 | $50.76 |
| Current liabilities | ||||
| Accounts payable | $4.55 | $4.09 | $3.32 | $4.97 |
| Deferred revenue | $0.81 | $0.85 | ||
| Short long term debt | $11.53 | $10.86 | $5.21 | |
| Total current liabilities | $19.87 | $19.13 | $17.81 | $13.99 |
| Long term debt | $21.66 | $22.63 | $22.59 | $31.88 |
| Total noncurrent liabilities | $23.26 | $23.27 | $31.88 | |
| Total debt | $34.16 | $33.45 | $37.09 | |
| Total liabilities | $42.37 | $42.4 | $41.09 | $45.87 |
| Shareholders' equity | ||||
| Retained earnings | -$336.56 | -$326.71 | -$317.21 | -$308.25 |
| Other shareholder equity | -$0.69 | -$0.54 | -$0.46 | -$0.65 |
| Total shareholder equity | $16.91 | $12 | $4.96 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.47 | $5.47 | $17.05 | $8.09 |
| Short term investments | ||||
| Net receivables | $2.18 | $2.47 | $2.14 | $4.56 |
| Inventory | $9.19 | $7.02 | $4.9 | $2.78 |
| Total current assets | $27.96 | $22.32 | $28.43 | $17.79 |
| Long term investments | ||||
| Property, plant & equipment | $1.67 | $1.7 | $1.73 | $0.68 |
| Goodwill & intangible assets | $20.12 | $22.44 | $22.65 | $24.34 |
| Total noncurrent assets | $22.8 | $25.13 | $24.83 | $25.05 |
| Total investments | ||||
| Total assets | $50.76 | $47.45 | $53.27 | $42.84 |
| Current liabilities | ||||
| Accounts payable | $4.97 | $5.81 | $4.93 | $4.76 |
| Deferred revenue | ||||
| Short long term debt | $5.21 | $16.37 | $3.42 | $3.79 |
| Total current liabilities | $13.99 | $30.34 | $15.47 | $13.22 |
| Long term debt | $31.88 | $17.74 | $25.94 | $12.42 |
| Total noncurrent liabilities | $31.88 | $18.47 | $25.94 | $12.42 |
| Total debt | $37.09 | $34.84 | $29.36 | $16.21 |
| Total liabilities | $45.87 | $48.11 | $41.41 | $25.64 |
| Shareholders' equity | ||||
| Retained earnings | -$308.25 | -$266.95 | -$219.49 | -$166.9 |
| Other shareholder equity | -$0.65 | -$0.68 | ||
| Total shareholder equity | $4.96 | -$0.66 | $11.61 | $17.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.11 | $2.72 | $2.35 | $2.3 |
| Cost of revenue | $0.43 | $0.43 | $0.69 | |
| Gross Profit | $2.57 | $2.29 | $1.92 | $1.61 |
| Operating activities | ||||
| Research & development | $3.65 | $4.31 | $3.46 | |
| Selling, general & administrative | $5.84 | $5.82 | $5.34 | |
| Total operating expenses | $9.83 | $9.49 | $10.14 | $9.11 |
| Operating income | -$7.2 | -$8.21 | -$7.5 | |
| Income from continuing operations | ||||
| EBIT | -$9.6 | -$8.62 | -$8.92 | |
| Income tax expense | ||||
| Interest expense | -$2.93 | -$0.11 | $0.61 | $0.25 |
| Net income | ||||
| Net income | -$9.85 | -$9.49 | -$9.23 | -$9.17 |
| Income (for common shares) | -$9.49 | -$9.23 | -$9.17 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.76 | $11.96 | $4.33 | $9.38 |
| Cost of revenue | $2.04 | $2.02 | $2.33 | $3.28 |
| Gross Profit | $7.72 | $9.94 | $2 | $6.11 |
| Operating activities | ||||
| Research & development | $18.6 | $17.65 | $15.08 | $6.41 |
| Selling, general & administrative | $23.05 | $26.7 | $26 | $21 |
| Total operating expenses | $42.02 | $44.35 | $42.71 | $32.75 |
| Operating income | -$34.29 | -$34.41 | -$40.71 | -$26.65 |
| Income from continuing operations | ||||
| EBIT | -$34.92 | -$34.73 | -$44.18 | -$31.02 |
| Income tax expense | ||||
| Interest expense | $6.38 | $12.72 | $8.42 | $2.79 |
| Net income | ||||
| Net income | -$41.3 | -$47.45 | -$52.6 | -$33.81 |
| Income (for common shares) | -$41.3 | -$47.45 | -$52.59 | -$38.65 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$9.49 | -$9.23 | -$9.17 | |
| Operating activities | ||||
| Depreciation | $0.56 | $0.61 | $0.59 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.38 | $0.58 | $0.58 | |
| Total cash flows from operations | -$8.17 | -$7.05 | -$7.45 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.02 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $12.67 | $12.49 | $11.25 | |
| Net borrowings | -$0.09 | -$0.22 | -$0.61 | |
| Total cash flows from financing | $28.37 | $12.57 | $12.27 | $10.65 |
| Effect of exchange rate | $0 | -$0.01 | -$0.02 | $0.04 |
| Change in cash and equivalents | $6.8 | $4.38 | $5.2 | $3.24 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$41.3 | -$47.45 | -$52.6 | -$33.81 |
| Operating activities | ||||
| Depreciation | $2.39 | $2.29 | $1.81 | $2.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.11 | $3.32 | $3.97 | $3.81 |
| Total cash flows from operations | -$33.24 | -$33.1 | -$34.97 | -$15.28 |
| Investing activities | ||||
| Capital expenditures | -$1.68 | -$0.01 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$1.68 | -$0.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $33.34 | $20.46 | $35.62 | $7.76 |
| Net borrowings | -$0.95 | $2.72 | $8.11 | $12.06 |
| Total cash flows from financing | $34.23 | $23.18 | $43.94 | $19.49 |
| Effect of exchange rate | $0.01 | $0.02 | ||
| Change in cash and equivalents | $1 | -$11.58 | $8.96 | $4.21 |
News
Fundamentals
| Market cap | $21.47M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 10.42M |
| Revenue | $10.48M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$37.74M |
| Revenue Q/Q | 10.49% |
| Revenue Y/Y | -2.25% |
| P/E ratio | -0.57 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.05 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 1.27 |
| EPS | -$3.62 |
|---|---|
| ROA | -66.78% |
| ROE | N/A |
| Debt/Equity | 9.25 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.84 |
| Quick ratio | 1.36 |